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White UA, Maier J, Zhao P, Richard AJ, Stephens JM. The
modulation of adiponectin by STAT5-activating hormones. Am J
Physiol Endocrinol Metab 310: E129–E136, 2016. First published
November 25, 2015; doi:10.1152/ajpendo.00068.2015.—Adiponectin
is a hormone secreted from adipocytes that plays an important role in
insulin sensitivity and protects against metabolic syndrome. Growth
hormone (GH) and prolactin (PRL) are potent STAT5 activators that
regulate the expression of several genes in adipocytes. Studies have
shown that the secretion of adiponectin from adipose tissue is de-
creased by treatment with PRL and GH. In this study, we demonstrate
that 3T3-L1 adipocytes treated with GH or PRL exhibit a reduction in
adiponectin protein levels. Furthermore, we identified three putative
STAT5 binding sites in the murine adiponectin promoter and show
that only one of these, located at 3,809, binds nuclear protein in a
GH- or PRL-dependent manner. Mutation of the STAT5 binding site
reduced PRL-dependent protein binding, and supershift analysis re-
vealed that STAT5A and -5B, but not STAT1 and -3, bind to this site
in response to PRL. Chromatin immunoprecipitation (IP) analysis
demonstrated that only STAT5A, and not STAT1 and -3, bind to the
murine adiponectin promoter in a GH-dependent manner in vivo.
Adiponectin promoter/reporter constructs were responsive to GH, and
chromatin IP analysis reveals that STAT5 binds the adiponectin
promoter in vivo following GH stimulation. Overall, these data
strongly suggest that STAT5 activators regulate adiponectin transcrip-
tion through the binding of STAT5 to the 3,809 site that leads to
decreased adiponectin expression and secretion. These mechanistic
observations are highly consistent with studies in mice and humans
that have high GH or PRL levels that are accompanied by lower
circulating levels of adiponectin.
signal transducer and activator of transcription 5
GROWTH HORMONE (GH) is known to have profound effects on
adipocyte metabolism (reviewed in Ref. 8), such as attenuating
lipogenesis and stimulating lipolysis (35, 56). The effects of
prolactin (PRL) have been well characterized in mammary
tissues, and yet there is also evidence suggesting that this
hormone can act within adipose tissue in mice and humans (31,
36) to modulate lipolysis (11, 32). It is well known that GH and
PRL induce signaling via the JAK/STAT pathway, and STAT5
proteins are potently activated by these hormones (reviewed in
Ref. 46). However, few direct molecular targets for the actions
of GH and PRL in fat cells have been identified.
Multiple lines of evidence suggest that STAT5 proteins can
modulate adipocyte function. During differentiation of 3T3-L1
adipocytes, the expression levels of STAT5A and -5B are
highly induced (50). In addition, GH-dependent adipogenesis
of 3T3-F442A cells is attenuated by STAT5 antisense oligo-
nucleotides (58), and constitutively active STAT5 can replace
the requirement for GH in adipogenesis of these cells (48).
Moreover, ectopic expression of STAT5A has been shown to
confer adipogenesis in both 3T3-L1 preadipocytes (38) and in
nonprecursor fibroblast cell lines (12). Transgenic deletion of
STAT5A, STAT5B, or both STAT5 genes in mice results in
significantly reduced fat pad sizes compared with wild-type
mice (53). Other in vivo studies indicate that fibroblasts ectop-
ically expressing STAT5 can form ectopic fat pads at the site
of injection when injected into athymic mice (51). In primary
cultures of adipose tissue from STAT5-null mice, GH is unable
to stimulate lipolysis as it does in adipocytes from wild-type
animals (10). Collectively, these studies and others (43) sug-
gest that STAT5 proteins mediate some of the physiological
effects of GH on fat cell differentiation and lipid metabolism.
Although evidence from numerous independent laboratories
suggests that STAT5 proteins can modulate adipocyte physi-
ology (10, 12, 38, 43, 48, 50, 51, 53, 58), very few studies have
identified direct STAT5 target genes in adipocytes. In previous
studies, we observed that GH- or PRL-induced inhibition of
fatty acid synthase (FAS) transcription was mediated by a
STAT5A-binding site in the rat FAS promoter (18). In addi-
tion, the promoter for acyl-CoA oxidase, the rate-limiting
enzyme in peroxisomal fatty acid -oxidation, contains a
STAT5 binding site that increases its gene expression in fat
cells as a result of treatment with GH (7). We also identified a
STAT5 binding site in the murine pyruvate dehydrogenase
kinase 4 (PDK4) promoter that mediates the PRL and GH
induction of PDK4 expression in adipocytes (57). PDK4 ex-
pression is associated with decreased insulin-responsive glu-
cose uptake in these cells (57) and may correlate with GH-
induced systemic insulin resistance. Our current efforts are to
identify other genes associated with glucose or lipid metabo-
lism that are directly modulated by STAT5 proteins in fat cells.
Adiponectin is an adipokine that plays an important role in
the regulation of glucose, lipid, and energy metabolism (21,
45) by suppressing hepatic gluconeogenesis and increasing
insulin sensitivity (reviewed in Ref. 54). Low serum levels of
adiponectin are associated with obesity and insulin resistance
in both animals and humans (1, 19, 20, 30, 39) (reviewed in
Ref. 16). Adiponectin administration can alleviate insulin re-
sistance (13). Some studies have shown that STAT5 activator
GH or PRL can reduce the production and secretion of adi-
ponectin. Mice treated with bovine GH have decreased total
and high-molecular weight adiponectin (34). In cultured hu-
man adipose tissue, adiponectin secretion is significantly sup-
pressed by PRL (40). In transgenic animal models with in-
creased GH signaling, circulating levels of adiponectin are
Address for reprint requests and other correspondence: J. M. Stephens,
Pennington Biomedical Research Center, Adipocyte Biology Laboratory, Ba-
ton Rouge, LA 70808 (e-mail: jsteph1@lsu.edu).
Am J Physiol Endocrinol Metab 310: E129–E136, 2016.
First published November 25, 2015; doi:10.1152/ajpendo.00068.2015.
0193-1849/16 Copyright © 2016 the American Physiological Societyhttp://www.ajpendo.org E129
Downloaded from journals.physiology.org/journal/ajpendo at LSU Louisiana State Univ (130.039.060.163) on September 23, 2021.
decreased. Conversely, mice lacking the GH receptor or ex-
pressing a GH antagonist have increased circulating levels of
this hormone (3). Serum adiponectin levels are reduced in
patients with acromegaly and normalized after correction of
GH excess (29). Also, patients with high circulating PRL due
to prolactinomas have hypoadiponectinemia (9, 14). Collec-
tively, these results suggest that GH and PRL, two STAT5-
activating hormones, can inhibit adiponectin expression and/or
secretion in mouse and man.
The primary objective of our study was to determine
whether GH and PRL could modulate adiponectin expression
in a STAT5-mediated manner. We examined the modulation of
adiponectin by STAT5 activators in adipocytes. Our studies
clearly demonstrate that both GH and PRL inhibit adiponectin
expression and production in fat cells. We identified three
putative STAT-binding elements in the adiponectin promoter
and show that only one of these sites specifically and signifi-
cantly binds STAT5 in vitro and in vivo. Chromatin immuno-
precipitation (ChIP) analysis and mutagenesis studies indicate
that STAT5 binds the adiponectin promoter in vivo, and
attenuation of adiponectin transcription is dependent upon the
STAT5 binding site that we validated. However, the adiponec-
tin mRNA is very stable, and changes in adiponectin transcrip-
tion are not evident at the protein level for several days after
treatment with STAT5-activating hormones. These novel stud-
ies provide highly mechanistic data that support numerous
studies showing that elevated GH and PRL can reduce adi-
ponectin expression in both mice and humans.
MATERIALS AND METHODS
Materials. Dulbecco’s modified Eagle’s medium (DMEM) was
purchased from Sigma. Fetal bovine and calf sera were purchased
from Hyclone. Commercial antibodies against STAT1 (Upstate Bio-
technology), STAT3, and STAT5A (Santa Cruz Biotechnology) and
adiponectin (ThermoFisher Scientific) were purchased. Murine GH
and murine PRL were from ProSpec. Mouse tumor necrosis factor-
was purchased from Gibco (Life Technologies). Rosiglitazone was
obtained from Cayman Chemical. [-32P]dCTP and deoxynucleotides
(dATP, dTTP, and dGTP) were purchased from GE Healthcare or
Amersham Biosciences. Klenow fragment was from Promega.
Cell culture. Murine 3T3-L1 preadipocytes were plated and grown
to 2 days postconfluence in DMEM with 10% calf serum. Medium
was changed every 48 h. Cells were induced to differentiate by
changing the medium to DMEM containing 10% fetal bovine serum
(FBS), 0.5 mM 3-isobutyl-1-methylxanthine, 1 M dexamethasone,
and 1.7 M insulin. This medium was replaced with DMEM contain-
ing 10% fetal bovine serum and 425 nM insulin for 48 h. Adipocytes
were then maintained in DMEM with 10% FBS for 8 days.
Preparation of whole cell extracts. Cell monolayers were harvested
in a nondenaturing buffer containing 10 mM Tris (pH 7.4), 150 mM
NaCl, 1 mM EGTA, 1 mM EDTA, 1% Triton X-100, 0.5% Nonidet
P-40, 1 M phenylmethylsulfonyl fluoride, 1 M pepstatin, 50 mU
trypsin inhibitory aprotinin, 10 M leupeptin, and 2 mM sodium
vanadate. Samples were extracted for 30 min on ice and centrifuged
at 15,000 rpm at 4°C for 15 min. Media samples were collected from
adipocyte culture, and 1 M pepstatin was added prior to 80°C
storage. Supernatants containing whole cell extracts or media samples
were analyzed for protein content by BCA analysis (Pierce) according
to the manufacturer’s instructions.
Nuclear and cytosolic extract preparation. Monolayers of 3T3-L1
adipocytes were harvested in a nuclear homogenization buffer, as
described previously (60). Nonidet P-40 was added to a final concen-
tration of 0.15%, and cells were homogenized with 16 strokes in a
Dounce homogenizer. Homogenates were centrifuged at 1,500 rpm
for 6 min at 4°C. The supernatants were saved and frozen as cytosolic
extracts and the pellets of intact nuclei were resuspended in half of the
previous volume of nuclear homogenization buffer and centrifuged as
before. The resulting nuclear pellet was resuspended in a buffer of 20
mM HEPES (pH 7.9), 0.42 M NaCl, 1.5 mM MgCl2, 0.2 mM EDTA,
and 25% glycerol. For electrophoretic mobility shift assays, the
nuclear suspensions were incubated on ice for 30 min and then
drawn twice through a 20-gauge needle. The nuclear extracts were
centrifuged for 10 min at 10,000 rpm, and supernatants were taken for
protein analysis by BCA or stored in aliquots at 80°C.
RNA analysis. Total RNA was isolated from cell monolayers with
Trizol (Invitrogen) according to the manufacturer’s instructions, with
minor modifications. For Northern blot analysis, 15 g of total RNA
was denatured in formamide and electrophoresed through a formal-
dehyde-agarose gel. The RNA was transferred to Zeta Probe-GT
Table 1. STAT consensus sequences in the adiponectin
promoter




3,809 (mutant) TTAAGGGAA No
-Casein TTCTAGGAA Yes
PRL, prolactin.
Fig. 1. The identification of a prolactin (PRL)-responsive region in the murine
adiponectin promoter that binds STAT5A and STAT5B. A: nuclear extracts
were prepared from adipocytes that were untreated () or treated () with 1
nM PRL for 15 min, and protein-DNA complexes were resolved by electro-
phoretic mobility shift assay (EMSA). For each sample, 15 g of protein was
incubated with 100,000 counts/min of the indicated 32P-labeled probes.
B: wild-type (WT) and mutant (M) probes (see Table 1) were incubated with
10 g of nuclear extract from PRL-treated cells and subjected to EMSA
analysis. C: 32P-labeled probes with an activity of 50,000 counts·min1·ml1
were serially diluted with 50 nM to 5 M of unlabeled probe and combined
with 10 g of PRL-treated nuclear extracts. Five micromoles of unlabeled
-casein probe was used as a positive control. Complexes were resolved by
EMSA. D: 10 g of PRL-treated nuclear extract was incubated with 1.5 g of
the indicated STAT antibodies for 1 h at room temperature prior to incubation
with 50,000 counts·min1·ml1 of radiolabeled 3,809 probe. Complexes
were resolved by EMSA. A–D represent experiments each performed individ-
ually 3 times.
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(Bio-Rad) in a buffer containing 75 mM sodium citrate tribasic, 10
mM NaOH, and 750 mM NaCl. Probes were labeled by random
priming using Klenow fragment and [-32P]dCTP.
Electrophoretic mobility shift assays. Double-stranded oligonucle-
otides were end-labeled with [-32P]dCTP using Klenow. Binding
reactions were performed with nuclear extracts as described (44).
Protein-DNA complexes were resolved and visualized as described
previously (18). For cold competition analysis to determine specificity
of binding, nuclear extracts were incubated on ice for 15 min with
unlabeled oligonucleotide before the addition of 32P-labeled probe.
For supershift analysis, nuclear extracts were preincubated with anti-
body for 1 h at room temperature.
Plasmid construction. The region corresponding to the 3,809 site
and flanking regions were amplified by PCR. Restriction sites for NheI
and HindIII were added to primer ends to facilitate directional clon-
ing. PCR reaction conditions consisted of 45 l of platinum PCR
supermix HiFi (Invitrogen), 0.5 l of each primer from a 20-pM
stock, and 100 ng of genomic DNA from 3T3-L1 adipocytes. PCR
was performed using an MJ Research PTC-100 machine set to cycle
at 1) 94°C for 2 min, 2) 94°C for 30 s, 3) 55°C for 30 s, and 4) 68°C
for 4.5 min, which was then repeated 35 times beginning with step 2.
Amplicons were purified and digested with NheI and HindIII accord-
ing to the manufacturer’s instructions (New England Biolabs). The
pGL4.27 luciferase vector (Promega) was also digested with NheI and
HindIII and ligated to previously digested amplicon by using T4 DNA
ligase according to the manufacturer’s instructions (New England
Biolabs) to create adiponectin promoter/luciferase reporter pGL4
vectors. The STAT consensus sequence in the vectors was mutated to
alter the binding site (refer to Table 1) using the QuickChange II Site
Directed Mutagenesis kit (Stratagene). Plasmids were sequenced for
verification of wild-type and mutagenic nucleotide sequences using
Big Dye Terminator Extension Reactions (ABI).
Transfection of 3T3-L1 adipocytes. Six-well plates of 3T3-L1 cells
were transfected on day 3 of differentiation after addition of DMEM
containing 5% FBS. Cells were cotransfected with 2.5 g of a plasmid
containing 4.5 kb of the adiponectin promoter 2-kb fragment contain-
ing the 3,809 site and 250 ng of pGL-TK/renilla vector to control for
transfection efficiency using Fugene 6 (Roche). Cells were maintained
in the presence or absence of 1 nM murine GH. Thirty hours
posttransfection, cell lysates were harvested and assayed for firefly
and Renilla luciferase using the Dual Luciferase Reporter System
(Promega). Relative light units were calculated by dividing firefly
luciferase activity values by Renilla luciferase.
Chromatin immunoprecipitation. A SimpleChIP enzymatic ChIP
kit (Cell Signaling Technology) was used for the ChIP assay. Mature
3T3-L1 adipocytes were serum deprived overnight. Cells were treated
with murine GH for 30 min and then cross-linked with formaldehyde
and glycine. Chromatin extracts were prepared according to the
manufacturer’s protocol. The STAT5A antibody used for immuno-
precipitation was purchased from Santa Cruz Biotechnology. Purified
DNA was quantified by real-time PCR with SYBR Green Supermix
and ROX buffer (Takara). Real-time PCR was performed with fol-
lowing primers: CTGTAGCTATACTGATGGTTGTGAGCC (for-
ward) and CTTTAGACTGGAGCAACTGGAGCC (reverse). The
formula used to calculate the percentage of input was as follows:
%input  2%  2(CT 2% input sample  CT IP sample)  k.
RESULTS
GH and PRL are potent STAT5 activators, and evidence
suggests that these hormones alter circulating adiponectin lev-
els; thus we hypothesized that the adiponectin promoter con-
tains putative STAT5 binding sites that confer GH and/or PRL
responsiveness. We cloned the murine adiponectin promoter
and searched for the presence of STAT consensus sites. Se-
quence analysis confirmed that the cloned promoter was 100%
homologous to Genbank NT_039624.7 Typically, STAT pro-
teins bind a core palindromic sequence, TTC NNN GAA, but
selective variation can occur in particular nucleotide positions.
As shown in Table 1, an analysis of the murine adiponectin
promoter resulted in the identification of three sites with
substantial homology to the STAT consensus sequence.
To evaluate these potential STAT binding sites, we per-
formed a series of electrophoretic mobility shift assays (EM-
SAs). For these experiments, an oligonucleotide probe contain-
ing 9 bp of the core STAT motif with 6 bp of flanking sequence
on either end was incubated with nuclear extracts prepared
from 3T3-L1 adipocytes that were untreated or treated acutely
with PRL for 15 min. As shown in Fig. 1A, PRL did not induce
the binding of nuclear protein complexes to regions 3,196 to
Fig. 2. Chronic growth hormone (GH) treatment results in a modest decrease
in adiponectin mRNA levels. Fully differentiated 3T3-L1 adipocytes were
maintained in DMEM containing 10% FBS and treated with 2 nM GH every
24 h until harvested at the times indicated. Following treatment, total RNA was
collected from cells, and 20 g of each total RNA was electrophoresed,
transferred to nylon, and subjected to Northern blot analysis. This is a
representative experiment performed independently 3 times.
Fig. 3. Adiponectin mRNA is highly stable in adipocytes. Total RNA was
isolated from fully differentiated 3T3-L1 adipocytes following treatment with
5 g/ml actinomycin D for the various periods of time indicated at the top.
Control samples were isolated at the start of the experiment (time 0). Twenty
micrograms of total RNA was electrophoresed, transferred to nylon, and
subjected to Northern blot analysis for peroxisome proliferator-activated re-
ceptor-	 (PPAR	), adiponectin, and -actin. This is a representative experi-
ment independently performed twice.
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3,188 or 3,394 to 3,386 of the adiponectin promoter.
However, we did observe PRL-induced binding by a nuclear
protein complex to the 3,809 to 3,801 region of the
adiponectin promoter. In addition, we observed similar results
using GH-treated nuclear extracts (data not shown). The in-
duction of binding by a PRL-activated protein complex to the
rat -casein STAT5 binding site (47) is included as a positive
control. These data demonstrate that one of the three STAT
elements in the adiponectin promoter binds nuclear adipocyte
protein in a PRL-dependent manner in vitro. To examine the
specificity of binding, an EMSA was performed, using a
mutant version of the 3,809 to 3,801 oligonucleotide (see
Table 1), in which two nucleotides were changed. As shown in
Fig. 1B, there was no detectable binding to the mutant form of
the binding site following PRL stimulation. In addition, bind-
ing of the PRL-activated protein complex was successively
competed away with increasing concentrations of the unlabeled
3,809 to 3,801 oligonucleotide probe (Fig. 1C). As antic-
ipated, binding was also competed away with the STAT5
binding site of the rat -casein promoter.
To determine the specific STAT proteins in the DNA bind-
ing complex, we performed supershift analysis using antibod-
ies directed against STAT proteins known to be expressed in
adipocytes. As shown in Fig. 1D, our data clearly demonstrate
that the protein complex induced by PRL was fully super-
shifted with a STAT5A antibody (lane 4) and weakly super-
shifted with a STAT5B antibody (lane 5). STAT1 and STAT3
antibodies had no effect on the mobility of the complex (lanes
6 and 7). Highly similar results were also obtained following
GH treatment (data not shown).
Because both GH and PRL were shown to modulate the
adiponectin promoter, we observed the effects of GH on
adiponectin RNA. Total RNA was isolated from fully differ-
entiated 3T3-L1 adipocytes after treatment with GH. As shown
in Fig. 2, adiponectin mRNA was readily detectable in un-
treated adipocytes, and GH had only a modest effect on
adiponectin mRNA levels following prolonged GH treatment.
Both ap2 and ethidium bromide staining of 28S and 18S RNA
were included as loading controls. Because we did not observe
a substantial effect of GH on adiponectin mRNA, we per-
formed a half-life experiment to determine the longevity of
adiponectin mRNA expression. Total RNA was isolated from
fully differentiated 3T3-L1 adipocytes after treatment with
actinomycin D for the times indicated. As shown in Fig. 3,
adiponectin has a relatively long half-life compared with
PPAR	 and -actin. Ethidium bromide staining of 28S and
18S RNA is included as a loading control. To our knowledge,
this is the first study to demonstrate the stability of the
adiponectin mRNA. Additional data indicate that neither GH
or PRL alters the stability of adiponectin mRNA (data not
shown).
Several studies have shown that both GH and PRL can
modulate adiponectin levels (2, 3, 6, 34, 40). Therefore, we
investigated the effects of these STAT5 activators on adiponec-
tin protein levels in fat cells. Mature 3T3-L1 adipocytes were
exposed to GH or PRL for various treatment times, and whole
Fig. 4. Chronic PRL (A) or GH treatment (B) decreases
the expression of adiponectin in 3T3-L1 adipocytes.
Fully differentiated 3T3-L1 adipocytes were maintained
in DMEM containing 10% FBS and treated with 1 nM
PRL or 2 nM GH every 24 h until harvested at the times
indicated. Forty micrograms of whole cell extract was
subjected to SDS-PAGE and transferred to nitrocellu-
lose for Western blot analysis. STAT5A levels are
shown as a loading control. Both A and B represent
experiments each performed independently 3 times.
Fig. 5. Adiponectin secretion is decreased by STAT5-
activating hormones. Mature 3T3-L1 adipocytes were
treated daily with a 1-nM dose of PRL, GH, or TNF.
Media samples were harvested at the indicated times,
and 100 g of each sample was subjected to Western
blot analysis. This is a representative experiment per-
formed independently 3 times. CTL, control; Rosi,
rosiglitazone; SOD3, superoxide dismutase 3.
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cell extracts were isolated to examine adiponectin protein
expression. Although neither the 12- nor the 24-h PRL incu-
bations had a substantial effect on adiponectin levels, chronic
treatments of 48, 72, and 96 h caused a significant decrease in
adiponectin protein (Fig. 4A). STAT5A protein levels are
included for even loading. Similar results are shown for GH in
Fig. 4B. Western blot quantitation is shown in Fig. 4, A and B,
right. We also demonstrated that both GH and PRL inhibited
the secretion of adiponectin following a 96-h incubation of
3T3-L1 adipocytes (Fig. 5). Western blot quantitation is shown
in Fig. 5, right. TNF, a proinflammatory cytokine known to
downregulate adiponectin expression, was used as a positive
control. The thiazolidinedione rosiglitazone was included as a
negative control. The levels of the extracellular form of super-
oxide dismutase 3 were not affected by GH or PRL but were
inhibited by TNF.
Our data demonstrate that STAT5 activators can inhibit
adiponectin expression. Therefore, we hypothesized that GH
and PRL may also affect adiponectin promoter activity. Hence,
3T3-L1 cells were transiently transfected with a luciferase
construct containing the first 4.5 kb of the adiponectin pro-
moter. The adipocytes were treated with GH, and after 48 h,
luciferase activity was measured as described in MATERIALS AND
METHODS. We observed that GH treatment significantly reduced
relative luciferase activity, as shown in Fig. 6A, demonstrating
that a 4.5-kb fragment of the adiponectin promoter (3,985
to 503; ENSMUST00000023593) is sensitive to GH. We
also made a vector containing 2 kb (3,985 to 1,995;
ENSMUST00000023593) of the adiponectin promoter re-
gion containing the 3,809 to 3,801 STAT5A binding
site. Transfection of the wild-type and mutant constructs of
both the 4.5- and 2-kb promoter/reporter vectors into
Fig. 6. Treatment with GH modulates adiponectin pro-
moter/reporter construct activity in 3T3-L1 adipocytes.
A: fully differentiated adipocytes were transiently trans-
fected with a vector containing 5 kb of the adiponectin
promoter and a firefly luciferase reporter. GH-treated
cells were stimulated with 1 nM GH for 48 h, and a
cytomegalovirus/Renilla vector was cotransfected to
normalize for transfection efficiency. Relative light
units (RLU) were calculated by dividing firefly lu-
ciferase activity by Renilla luciferase activity. Each
condition was performed in triplicate. In addition, each
experiment was performed independently 3 times. B:
vectors containing 4.5 kb or a selected 2 kb of the
adiponectin promoter driving a firefly luciferase re-
porter were transfected into mature adipocytes. Vectors
containing mutants of the 3,809 site were also used.
Fig. 7. STAT5A, but not STAT1 and -3, specifically
and significantly binds the murine adiponectin pro-
moter in vivo. Mature 3T3-L1 adipocytes were un-
treated or treated with 1 nM GH for 30 min and then
cross-linked with formaldehyde. Chromatin extracts
were prepared and immunoprecipitated with
STAT1, STAT3, or STAT5 antibody. Immunopre-
cipitation products were subjected to quantitative
real-time PCR analysis for potential STAT binding
sites within the murine adiponectin at promoter
regions 3,196 (A), 3,394 (B), and 3,809 (C).
The percentage of input was calculated and normal-
ized to the CTL.
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3T3-L1 adipocytes revealed that the basal level of luciferase
activity was significantly increased by mutation of the
STAT5A binding site in the adiponectin promoter (Fig. 6B).
Notably, the activity of the upstream 2-kb fragment was
greater than the 4.5-kb construct, suggesting that there are
other sites in the proximal promoter that dampen promoter
activity. Finally, we performed ChIP analysis to determine
whether STAT5 proteins bound to the adiponectin promoter in
vivo. As shown in Fig. 7, acute GH treatment resulted in a
statistically significant increase in STAT5A binding to the
3,809 site we identified and characterized in vitro (Fig. 1).
Although there was a modest increase in STAT5A binding to
the 3,196 site, the changes were not statistically significant.
Moreover, we did not observe a statistically significant differ-
ence in either STAT1 or STAT3 binding to the putative STAT
site in the adiponectin promoter (Fig. 7). Our in vitro and in
vivo observations are highly consistent. Overall, these data
clearly indicate that the 3,809 to 3,801 site of the adiponec-
tin promoter is sensitive to GH and also suggest that this site
confers the negative regulation of adiponectin by GH- and
PRL-activated STAT5A protein complexes.
DISCUSSION
Adiponectin, a hormone produced from adipocytes, is
known to enhance insulin sensitivity and have anti-inflamma-
tory actions. Although anterior pituitary hormones like GH and
PRL have been shown to reduce adiponectin expression, the
mechanism(s) for this regulation was not previously unidenti-
fied. We have identified a STAT5A binding site in the murine
adiponectin promoter. Collectively, our results demonstrate
that the STAT5A binding site in the adiponectin promoter
binds STAT5A in vivo and plays a role in decreasing adiponec-
tin promoter activity that eventually results in reduced adi-
ponectin expression and secretion.
An interesting observation that came from our studies was
that although acute treatment with STAT5-activating hor-
mones results in the binding of STAT5A to the promoter, it
takes several hours of GH or PRL treatment to observe de-
creased adiponectin mRNA and protein levels. This is likely
due to the fact that the adiponectin mRNA is very stable;
therefore, there is plenty of adiponectin mRNA accumulated in
the cell that continues to be a template for protein synthesis.
However, there are likely other transcriptional mediators of
adiponectin that act to induce adiponectin promoter activity.
The balance of this counterregulation is more challenging to
study given the prolonged stability of the adiponectin mRNA.
The promoter region of adiponectin has been studied exten-
sively. SREBP and C/EBP sites in the human adiponectin
promoter are required for basal transcription activity (28, 42).
Occupation of the PPAR	 site in the adiponectin promoter is
associated with transcriptional activation and induction by
thiazolidinediones (24). A liver receptor homolog-1 ite has
been shown to be important for basal and induced transcription
(24). The forkhead transcription factor O1 also binds the
adiponectin promoter to induce expression (4). Furthermore,
nuclear factor Y modulates the adiponectin promoter, and
mutation or deletion of the shared binding site results in
dramatically reduced transcription levels (41). To date, all of
the transcription factor binding sites in the adiponectin pro-
moter that have been studied are associated with basal tran-
scriptional activity or increased transcription. To our knowl-
edge, the STAT5 binding site in the murine adiponectin pro-
moter that is occupied following GH stimulation in vivo is the
first to be associated with decreased transcriptional activity of
adiponectin. Several single nucleotide polymorphisms that are
linked to type 2 diabetes and metabolic syndrome have been
identified in the adiponectin promoter (17, 27, 37, 55, 59), but
none of these include the STAT5 site we have identified.
A key question that arises for this research is whether
chronically elevated levels of GH and PRL are associated with
decreased adiponectin levels in vivo. In mice, there is no doubt
that a loss of GH or its receptor is associated with increased
adiponectin, and mice with excess GH have reduced adiponec-
tin expression (3). Humans with acromegaly or prolactinoma
have hypoadiponectinemia (9, 29, 52), although one study
showed an increase in adiponectin levels with acromegaly (49).
Future studies will need to address the potential ability of
STAT5-activating hormones to inhibit adiponectin in nonadi-
pocyte cells, including those found in skeletal muscle (5, 15),
the pituitary (25, 26), and the pancreas (33). Also, it is largely
accepted that the high molecular form of adiponectin is the
most cardioprotective. Hence, additional studies to assess the
ability of GH and PRL to modulate the high molecular forms
of adiponectin should be performed. In humans, there is some
evidence that GH treatment reduces the levels of high-molec-
ular weight adiponectin in rodents (22) and humans (23).
Despite some modest inconsistencies in the literature, the
majority of data support a role for PRL and GH, two STAT5-
activating hormones, in negatively regulating adiponectin lev-
els. Overall, our data provide mechanistic insight into the
transcriptional control of an important hormone that is modu-
lated in metabolic disease.
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